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Abstract This systematic review aimed to evaluate the long-
term (≥ 5 years) outcomes of bariatric surgery on diabetes
remission, microvascular and macrovascular events, and mor-
tality among type 2 diabetes (T2D) patients. Ten articles (one
randomized controlled trial and nine cohorts) met the inclu-
sion criteria and were included in this review. Pooled esti-
mates of nine cohort studies showed that surgery significantly
increased the diabetes remission (relative risk (RR) = 5.90;
95% CI 3.75–9.28), reduced the microvascular (RR = 0.37;
95% CI = 0.30–0.46) and macrovascular events (RR = 0.52;
95% CI 0.44–0.61), and mortality (RR = 0.21; 95% CI 0.20–
0.21) as compared to non-surgical treatment. Available evi-
dence suggests better remission and lower risks of microvas-
cular and macrovascular disease and mortality in the surgery
group as compared to non-surgical treatment group in T2D
patients after at least 5 years of follow-up.
Keywords Bariatric surgery . Type 2 diabetes . Diabetes
remission .Microvascular andmacrovascular complications .
Mortality . Long-term outcomes
Introduction
Type 2 diabetes is one of the fastest growing health problems
worldwide [1]. Intensive pharmaceutical and lifestyle interven-
tions typically result in a remission rate lower than 15% [2, 3].
Bariatric surgery, initially developed to treat severe obesity,
might be a more effective treatment for type 2 diabetes [4].
Bariatric surgery results in sustained weight loss in obese pa-
tients with type 2 diabetes [5]. For some patients, such weight
loss is accompanied by diabetes remission and improvement in
cardiovascular (CVD) risk factors (i.e., hypertension, hyperlip-
idemia) [5, 6]. It has been estimated that type 2 diabetes can be
resolved in 78% of the patients who undergo bariatric surgery
[7]. The superiority of bariatric surgery over non-surgical ther-
apy in inducing significant weight loss, diabetes remission, and
improvement in CVD risk factors has been proven in random-
ized controlled trials (RCTs) [8–10]. However, most of these
studies have limited follow-up time frames (≤ 2 years). Existing
evidence to determine towhich degree these short-term benefits
sustain over time is insufficient.
Two meta-analyses have shown that bariatric surgery was
associated with greater short-term (≤ 2 years) weight loss and
better glucose outcomes as compared with medical treatment
[11–13]. Two recent meta-analyses using studies that followed
patients up to 5 years also indicated that type 2 diabetes patients
receiving bariatric surgery had a significantly higher remission
rates (relative risks (RRs) ranged from 5.7 to 76.4) [14, 15]. To
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our knowledge, there is no systematic review and meta-analysis
synthesizing the effects of bariatric surgery on diabetes remission
beyond 5 years post-surgery among patients with type 2 diabetes
or of the impact on microvascular or macrovascular events, and
death as comparedwith non-surgical treatments. The objective of
this studywas to systematically review and evaluate the available
data comparing the remission rates, microcardiovascular and
macrocardiovascular events, and mortality rates to non-surgical
treatments in patients with type 2 diabetes.
Methods
Data Sources and Searches
Our systematic literature search was conducted in the National
Library of Medicine (PubMed/MEDLINE), SpringerLink,
and EMBASE databases to identify English articles published
from January 1, 1990 to October 31, 2016, using the keywords
of Bbariatric surgery,^ Bmetabolic surgery,^ Bdiabetes
surgery,^ Bgastric band,^ Bsleeve gastrectomy,^ Bgastric
bypass,^ Bduodenal switch,^ or Bbiliopancreatic diversion^
linked to Btype 2 diabetes,^ Bdiabetes mellitus,^ Bmedical
treatment or therapy,^ Bconventional treatment/therapy,^
Bdiabetes remission,^ Bdiabetes complication,^ Bdeath,^ or
Bmortality.^ This search resulted in 1238 abstracts, which were
further screened using the following inclusion criteria (Fig. 1).
Study Selection
We selected the original studies conducted with humans based
on the following criteria: (1) RCT or cohort studies, (2)
targeted on or had subgroup analysis in patients with T2D,
(3) reported at least one of the four outcomes of interest (dia-
betes remission, incidence of diabetes microvascular compli-
cations, incidence of diabetes macrovascular complications,
or mortality), and (4) patient follow-up for at least 5 years. If
separate articles from the same study were published, the ar-
ticle with the most updated data was selected. In case of du-
plicate publications, only one publication was included.
Among 1238 abstract identified, we excluded those not con-
ducted with humans (N = 80) or not using original data (e.g.,
reviews, comments or letters to the editor, or meta-analysis)
(N = 581). We reviewed 577 articles with full text. We also
performed a manual searching of references cited in original
studies and relevant review articles (N = 40). Among them, we
excluded studies that (1) did not have a comparison group or
case reports only (N = 388); (2) did not target on patients with
type 2 diabetes (N = 114); (3) did not target on diabetes re-
mission, microvascular complications, or macrovascular com-
plications (N = 74); and (4) had study duration less than 5 years
(N = 27). We also excluded two studies because they lacked
quantitative measures of associations between surgery and
outcomes and two articles because they were not based on
the most recent data from the original study. Finally, we in-
cluded 10 articles in the current systematic review.
Abstracts excluded (N=661)
• Had no original data (N=581)
• Did not conduct in humans (N=80)
Articles retrieved for full-text review (N=577)
Articles excluded (N=603)
• Did not have a comparison group or did not compare between surgery and medical
treatment or case report only (N=388)
• Did not target on patients with T2D (N=114)
• Did not assessed the associated between bariatric surgery on diabetes and diabetes
remission or microvascular complication or macrovascular complication (N=74)
• Had study duration less than 5 years (N=27)
Articles accepted for further screening 
(N=14)
Abstracts identified in PubMed, SpringerLink, and EMBASE (N=1,238)
Articles excluded (N=4)
• Did not report quantitative measure of association (N=2)  
• Articles published from the same studies (N=2)
Articles included in this study (N = 10)
(1 randomized controlled trial and 9 cohort studies)
Articles manually searched (N=40)
Fig. 1 Flow diagram of literature search
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Data Extraction
Two authors (BS and XT) extracted the data independently
using standardized data abstraction forms. Disagreements be-
tween reviewers were resolved by repeated examination of the
original articles and by discussions within the team. We ex-
tracted information from original studies using the last name
of the first author, year of publication, country of origin, pa-
tient body mass index (BMI) and age before the surgery, num-
ber of study participants, duration of follow-up, estimates of
the association between treatment and outcomes (odds ratio
(OR), RR, or hazard ratio (HR) and 95% confidence interval
(CI)), and variables adjusted in the statistical analyses. Two
additional authors (LC and LZ) reviewed all the extracted data
from the original articles to check on information accuracy.
Data Synthesis and Analysis
We pooled results for the meta-analysis only if there was a
minimum of three studies with the same research design and
outcomes were equal or greater than three. We performed
analyses for four different outcomes: (1) diabetes remission
(cessation of glucose-lowering medications, or achievement
of targeted glycated hemoglobin (HbA1c) thresholds) [16],
(2) incidence of microvascular complications (e.g., diabetic
nephropathy, neuropathy, or retinopathy), (3) incidence of
macrovascular complications (e.g., angina, not-fatal myocar-
dial infarction, stroke, revascularization of coronary, conges-
tive heart failure, or lower extremity arteries) [17], and (4) all-
cause mortality.
We assessed statistical heterogeneity using the
DerSimonian and Laird’s Q statistic and I2 statistic
(I2 > 50% was considered as meaningful level of heterogene-
ity). We also conducted a sensitivity analysis in which each
study was excluded, in turn, to evaluate the influence of that
particular study on the overall estimates. We examined the
publication bias using funnel plots and Begg’s test. All statis-
tical analyses were conducted with STATA 12.0 (Stata
Corporation, College Station, TX).
Results
Study Characteristics
Table 1 provides a summary of the main characteristics of the
10 studies (1 RCTand 9 cohorts) included in this review. Their
sample sizes ranged from 50 to 15,951 participants, and
follow-up time ranged from 5 to 15 years. Among all studies,
four were conducted in the USA [18–21], two in Sweden [17,
22], two in Italy [23, 24], one in UK [25], and one in China
[26]. All studies included both men and women, with the
average age close to 50 years. In all studies, the patients in
the comparison group were given non-surgical treatments for
type 2 diabetes (e.g., oral hypoglycemic medications and in-
sulin). One study mentioned that patients in the comparison
group were also given lifestyle coaching [19]. In the following
sections, we referred to the comparison group as the Bnon-
surgical treatment group.^ Among four US studies [18–21],
all racial groups were included, but the majority of patient
populations were white. With regard to the pre-operational
BMI, six studies included only patients with BMI ≥ 35 kg/
m2 [17–19, 21, 23, 24], two studies included patients with
BMI less than 35 kg/m2 [22, 25], and one study included
patients only with BMI ≤ 35 km/m2 [26].
Meta-Analysis of Cohort Studies
Diabetes Remissions
A total of 3204 type 2 diabetes patients from six studies
[17–19, 21, 25, 26] were included in this meta-analysis to
compare the diabetes remission rates between the bariatric
surgery and non-surgical treatment groups. Patients in the sur-
gery group had a higher rate of diabetes remission as com-
pared with those in the non-surgical treatment group
(RR = 5.90; 95% CI = 3.75–9.27) (Fig. 2a). There was no
significant heterogeneity across studies (Q = 0.04, I2 = 0%).
The funnel plots and Egger’s test suggested no publication
bias (P = 0.36).
Microvascular Complications
A total of 16,762 type 2 diabetes patients from four studies
[17, 19, 20, 23] were included in this meta-analysis to com-
pare the microvascular complications between the bariatric
surgery and non-surgical treatment groups. Patients in the sur-
gery group had a lower incidence of microvascular events as
compared with those in the non-surgical treatment group
(RR = 0.37; 95% CI = 0.30–0.46) (Fig. 2b). There was sig-
nificant heterogeneity across studies (Q = 6.60, I2 = 54.5%).
The funnel plots and Egger’s test suggested no publication
bias (P = 0.13).
Macrovascular Complications
A total of 29,026 type 2 diabetes patients from five studies
[17, 19, 20, 22, 23] were included in this meta-analysis to
compare macrovascular complications between the bariatric
surgery and non-surgical treatment groups. Patients in the sur-
gery group had lower incidence of macrovascular events as
compared with those in the non-surgical treatment group
(RR = 0.52; 95% CI = 0.44–0.61) (Fig. 2c). There was signif-
icant heterogeneity across studies (Q = 13.92, I2 = 71.3%).
The funnel plots and Egger’s test suggested no publication
bias (P = 0.32).
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Mortality
A total of 28,605 type 2 diabetes patients from four studies
[20–22, 26] were included in this meta-analysis to compare
the mortality rates between the bariatric surgery and non-
surgical treatment groups. The bariatric surgery group had a
lower mortality rate as compared with the non-surgical treat-
ment group (random model, RR = 0.21; 95% CI = 0.209–
0.213) (Fig. 2d). There was significant heterogeneity across
studies (Q = 55.85, I2 = 94.6%). The funnel plots and Egger’s
test suggested no publication bias (P = 0.30).
Sensitivity Analyses
Sensitivity analysis was performed to assess the influence of
each individual study on the pooled results by sequentially
repeating the meta-analysis excluding one single cohort study
from the analysis at a time. The results of the sensitivity anal-
yses suggested that the pooled point estimates were not sig-
nificantly affected by any single study (data not shown).
Evidence from a RCT
The only RCT study that followed patients after the surgery
for 5 years was conducted in Italy [24]. In this RCT, 40 T2D
patients were assigned to the surgery group and 20 were
assigned in the non-surgical treatment group. Of them, 15
patients (75%) in the non-surgical treatment group and 38
(95%) in the surgical group were followed at year 5. At year
5, the diabetes remission rate was 50.0% (15 of 38) in the
surgery group versus 0.0% (0 of 15) in the non-surgical treat-
ment group. One (2.6%) microvascular event (nephropathy)
was reported in the surgery group, and four (26.7%) events
(one retinopathy, one nephropathy, and two neuropathy) were
reported in the non-surgical treatment group (RR = 0.10; 95%
CI = 0.01–0.95). The incidence of coronary heart disease was
0.0% in the surgery group and 7.0% in the non-surgical treat-
ment group.
Discussion
Findings from our systematic review agree with the growing
body of evidence that shows the superiority of bariatric sur-
gery over non-surgical treatment in diabetes remission, as well
as a significant reduction in the risk of microvascular and
macrovascular diseases and mortality among type 2 diabetes
patients who have had their surgery for more than 5 years. In
the meta-analysis of cohort studies, we found that there was a
significantly higher rate of diabetes remissions, lower
A B
C D
Fig. 2 Forest plots of comparing remission rates of type 2 diabetes (a), microvascular complications (b), macrovascular complications (c), and mortality
(d) between bariatric surgery and conventional medical groups
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incidence of microvascular and macrovascular diseases, and
lower rate of death in the surgery group as compared to the
non-surgical treatment group. These results were confirmed
by one RCT study which followed the study participants for
5 years.
Diabetes Remission
Findings from our analysis were consistent with the results of
several previous meta-analyses that compared bariatric sur-
gery to medical treatment up to 5 years. For diabetes remis-
sion, a meta-analysis of studies that followed patients up to
24 months indicated that the remission rate ranged from 9.8 to
15.8 times higher in the surgical group as compared with
conventional therapy (63.5 vs. 15.6%) [27]. In our meta-
analysis of six cohort studies that following patients for at least
5 years (range 5–15 years), the diabetes remission was still
approximately six times higher in the surgical group than in
the medical treatment group, indicating that the superiority of
bariatric surgery over medical therapy on diabetes remission
can be maintained 5 years after surgery. A recent meta-
analysis of eight RCTs that followed patients from 1 to 5 years
also estimated that the pooled RR for diabetes remission was
5.76 (95% CI 3.15–10.55) for T2D patients in the bariatric
surgery group as compared with the medical treatment group
[15]. Another meta-analysis with six RCTs following patients
up to 5 years but only including the estimated effect of Roux-
en-Y gastric bypass (RYGB) found that the RR of diabetes
remission among bariatric surgery patients was much higher
(RR = 76.73; 95% CI 20.70–281.73) as compared to the non-
surgical patients [28]. In this review, we identified only one
RCT with follow-up time of 5 years [24]. According to this
RCT, 82% of the surgical type 2 diabetes patients were able to
maintain diabetes remission 5 years after the surgery.
Patients’ baseline characteristics that positively predicted
the diabetes remission after bariatric surgery include younger
age, shorter duration of diabetes, better glucose control, and
better β cell function [29]. Independent of these patients’
characteristics, weight loss followed by the surgery has been
shown as one of the most important mechanisms that help to
achieve better diabetes control. Percentage of weight loss has
been found to be positively associated with remission among
type 2 diabetes patients who underwent bariatric surgery [30].
However, improvement of glycemic control was observed in
the early post-operative period before significant weight loss
occurred, indicating that additional mechanisms might exist.
Other proposed mechanisms that explain the improvement of
glycemic control in type 2 diabetes patients after bariatric
surgery included changes in the secretion of gastrointestinal
hormones (e.g., glucagon-like peptide-1 (GLP-1), glucose-
dependent insulinotropic polypeptide (GIP), peptide YY, and
growth hormone-releasing peptides), improved capacity for
insulin secretion, and alterations in gut physiology and
microbiota [31]. The gastrointestinal hormones play critical
roles in the entero-insular axis in regulating insulin release
within the intestine [32]. GIP activates GLP-1 [33, 34], and
GLP acts on receptors located in pancreatic β cells, inhibiting
glucagon secretion, thereby resulting in glucose-dependent
insulin secretion [35]. The improved capacity for insulin se-
cretion after bariatric surgery may also be associated with
inhibition of apoptosis of β cells in pancreatic islets or tissue
repair [36].
Microvascular and Macrovascular Diseases
To our knowledge, this is the first meta-analysis demonstrat-
ing that bariatric surgery significantly reduces microvascular
and macrovascular events among type 2 diabetes patients as
compared to patients receiving only non-surgical treatment:
the estimated average reduction was 48% in macrovascular
risk and 79% in microvascular risk in cohort studies with
follow-up durations between 5 and 15 years. We only identi-
fied one RCTstudy that followed patients with type 2 diabetes
for 5 years. Results from this RCTalso showed approximately
90 and 97% decreases in microvascular and macrovascular
disease risks in the surgery group than in the medical group,
respectively. The greater improvement of glycemic control
and other risk factors for the microvascular and macrovascular
complications of type 2 diabetes may account for the reduced
incidence of microvascular and macrovascular events ob-
served in the surgery group. In addition, patients in the gastric
bypass group showed higher plasma concentrations of high-
density lipoprotein-cholesterol, suggesting that differences in
gastrointestinal anatomy might also induce distinct effects on
lipid metabolism [24]. We found significant heterogeneity
across the studies included in the meta-analysis of the micro-
vascular outcomes. One possible explanation is that we com-
bined diabetic nephropathy, neuropathy, or retinopathy events
all together, and indeed, there is substantial heterogeneity
across these di ffe ren t microvascular outcomes .
Unfortunately, studies included in this review and meta-
analysis did not allow us to conduct additional analysis, strat-
ified by type of these microvascular events. There are only
four studies reported long-term microvascular outcomes, and
none of them differentiated the type ofmicrovascular events in
their analyses. It is possible that bariatric surgery has varying
impacts on diabetic nephropathy, neuropathy, or retinopathy.
For example, diabetic retinopathy (DR) is the most common
microvascular complication of diabetes. Although overall im-
provement in glycemic control has been associated with re-
duced development of DR in the long term, concerns have
been raised about an initial worsening of the DR that may be
related to a rapid decrease in blood glucose levels that occur
after the bariatric surgery [37]. However, very few studies
have compared the short-term DR outcomes between bariatric
surgery and non-surgical treatment. One case-control study
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[38] and a RCT study [39] have reported no difference in DR
outcomes at 1 or 2 years after the surgery. Up to date, the effect
of bariatric surgery on DR remains inconclusive.
Mortality
This study is also the first meta-analysis that compares mor-
tality rates between bariatric surgery and non-surgical treat-
ment groups among type 2 diabetes patients. Of the four co-
hort studies that reported mortality between bariatric surgery
and comparison groups among patients with type 2 diabetes,
the mortality rate was 79% lower in the surgery group as
compared to the medical treatment group. Our results coincide
with other studies that compared the mortality rate after bar-
iatric surgery to medical treatment among general obese pa-
tients. A large retrospective cohort study in the USAwith the
maximum follow-up of 18 years (mean follow-up 7.1 years)
reported a 40% lower mortality in the gastric bypass group as
compared to the non-surgical treatment group in obese indi-
viduals [40]. In a meta-analysis conducted in 2014, which
included 10 studies among obese patients, comparing bariatric
surgery to non-surgical treatment, the estimated risk of death
from the pooled analysis was 52% (OR = 0.48; 95%
CI = 0.35–0.64) in the surgery group [41].
Consideration of Patients’ Age, Sex, Race, Surgery Type,
or Pre-Operational BMI
Given the nature of the data, it is not feasible for us to
conduct stratified analyses based on patients’ age, sex, race,
surgery type, or pre-operational BMI due to the small number
of selected studies or the lack of such data in the original
studies. Most studies included in this review included type 2
diabetes patients with BMI ≥ 35 kg/m2. In one study that
targeted Chinese type 2 diabetes patients with
BMI ≤ 35 kg/m2, the surgery was associated with greater
weight loss, a higher diabetes remission, and lower inci-
dence of death [26]. This finding is consistent with the
conclusion from two meta-analyses of relatively short-term
studies (≤2 years) in type 2 diabetes patients with BMI be-
tween 30 to 35 kg/m2 [11, 42] and < 30 kg/m2 [43], suggesting
that type 2 diabetes patients with BMI lower than 35 kg/m2
may also benefit from bariatric surgery. It has been suggested
that younger patients may benefit more from bariatric surgery,
but benefits do not differ by gender [29].
With regard to the surgery types, current evidence suggests
a progressive relationship of diabetes remission and type of
bariatric procedures: diabetes remission was found to be 48%
for laparoscopic adjustable gastric banding, 84% for gastric
bypass, and 98% for biliopancreatic diversion/duodenal
switch after 2 years of the surgery [5]. A recent study also
showed a 23% remission after gastric bypass and 29% after
sleeve gastrectomy after 5 years of the surgery. However, a
Swedish study did not observe significant differences in 10-
year diabetes remission by surgery type [17]. Little is known
whether CVD outcomes and morality rates vary by surgery
types. There is limited long-term data following individuals
who have undergone bariatric surgery and even more limited
data for newer procedures such as sleeve gastrectomy and
biliary pancreatic diversion (BPD) [44]. A number of alterna-
tive procedures to bariatric surgery, such as intragastric bal-
loons, endobarriers [45], and anastomosis gastric bypass [46],
have been evaluated in short-term studies, but not on CVD
events and mortality. Available data do not yet permit mean-
ingful conclusions on the comparative efficacy of different
surgical procedures in patients with type 2 diabetes.
Strengths and Limitations
Although evidence from cohort and RCT studies have sug-
gested greater benefits for patients with type 2 diabetes who
underwent bariatric surgery as compared with non-surgical
therapies, it is still debatable as to whether bariatric surgery
should be the preferred treatment for type 2 diabetes due to the
lack of long-term evidence. This review addressed this litera-
ture gap by summarizing and synthesizing the current avail-
able data on comparing diabetes remission rates, microvascu-
lar and macrovascular disease risks, and mortality rates be-
tween type 2 diabetes patients receiving bariatric surgery with
longer than 5-year follow-up and those who are receiving non-
surgical treatment alone. While long-term outcomes of bariat-
ric surgery seem to be favorable, interpretation of these find-
ings needs caution due to the inherent limitations of the
reviewed studies. The first limitation is that the diagnostic
criteria for diabetes remission and microvascular and
macrovascular disease outcomes varied considerably across
studies, thus potentially contributing to the heterogeneity de-
tected in the current meta-analysis and in return making the
comparison of results less compelling. The second limitation
is that the majority of the reviewed studies are observational in
design and thus are subject to selection biases. While all stud-
ies have controlled for important confounders in study design
or/and data analyses, the residual confounding cannot be
completely ruled out. The third limitation is that several stud-
ies have considerably low follow-up rates, which could affect
the internal validity of these studies. Lastly, the intensity of
care may be greater in patients who underwent surgery than
those receiving the non-surgery treatment, resulting in possi-
ble over-estimated effect. Nevertheless, findings from this
meta-analysis are supported by the similar results from previ-
ous meta-analyses of RCTs that followed patients for up to
5 years.
Conclusions
In conclusion, we identified 10 studies that followed patients
from 5 to 15 years in patients with type 2 diabetes. The results
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of this review and meta-analysis suggests a better remission
rate and a lower risk of macrovascular and microvascular dis-
ease and mortality in the surgery group as compared with
surgical treatment group. Larger RCTs with high follow-up
rates and data permitting the evaluation of different types of
bariatric surgery are warranted to provide guidelines for treat-
ment preferences for type 2 diabetes patients.
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